Molecular Profiling for Precision Oncology: Moving Beyond Feasibility and Safety
- 1 March 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (7) , 515-517
Abstract
In the article that accompanies this editorial, Sicklick et al. provide the results of their work to match next-generation sequencing to novel therapeutic drugs/combinations in metastatic cancer patients. While one of the largest studies of its kind, this application of “precision medicine” is ultimately limited by the need for a randomized trial to show that using molecular data for a very heterogeneous group of patients identifies therapies that are superior to existing standard-of-care agents.Keywords
This publication has 11 references indexed in Scilit:
- Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug CombinationsJournal of Clinical Oncology, 2026
- Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trialNature Medicine, 2025
- Genomics to select treatment for patients with metastatic breast cancerNature, 2022
- Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?JNCI: Journal of the National Cancer Institute, 2019
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT studyNature Medicine, 2019
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialThe Lancet Oncology, 2015
- Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400Clinical Cancer Research, 2015
- Evaluating Many Treatments and Biomarkers in Oncology: A New DesignJournal of Clinical Oncology, 2013
- Randomized Clinical Trials With Biomarkers: Design IssuesJNCI: Journal of the National Cancer Institute, 2010
- Issues in clinical trial design for tumor marker studiesSeminars in Oncology, 2002